Jonathan Young - 16 Dec 2024 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Operating Officer
Signature
/s/ Jonathan Young
Issuer symbol
AKRO
Transactions as of
16 Dec 2024
Net transactions value
$0
Form type
4
Filing time
18 Dec 2024, 21:08:34 UTC
Previous filing
12 Dec 2024
Next filing
06 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Award $0 +24,300 +12% $0.000000 228,083 16 Dec 2024 Direct F1
holding AKRO Common Stock 20,000 16 Dec 2024 By EA Irrevocable Trust F2
holding AKRO Common Stock 20,000 16 Dec 2024 By CM Irrevocable Trust F2
holding AKRO Common Stock 20,000 16 Dec 2024 By JL Irrevocable Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Award $0 +73,700 $0.000000 73,700 16 Dec 2024 Common Stock 73,700 $29.23 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in eight (8) equal semi-annual installments, commencing from December 16, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F2 These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3 This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing from December 16, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.